NKGen Biotech, Inc. (NKGN)

OTCMKTS · Delayed Price · Currency is USD

0.1800

+0.0192 (11.94%)

Mar 28, 2025, 3:35 PM EST

NKGen Biotech Employees

NKGen Biotech had 63 employees as of December 31, 2023.

Employees

63

Change

n/a

Growth

n/a

Revenue / Employee

n/a

Profits / Employee

-$769,492

Market Cap

7.34M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2023	63	-	-

Related Stocks

Company Name	Employees
Endo Inc.	2,931
Elite Pharmaceuticals	64
Glass House Brands	413
Northwest Biotherapeutics	25
CytoDyn	9
Silence Therapeutics	116
American Oncology Network	1,525

Employee Rankings

NKGen Biotech News

5 days ago - NKGen Biotech To Present Updated Troculeucel Data at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2025) - GlobeNewsWire
26 days ago - NKGen Biotech, Inc. to Transition from the Nasdaq Global Market to OTC Markets; Reverse Stock Split will not be Implemented - GlobeNewsWire
27 days ago - NKGen Biotech Announces Administration of First Dose of Troculeucel to Stroke Patient Under FDA-Cleared Compassionate Use Program - GlobeNewsWire
5 weeks ago - NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program - GlobeNewsWire
5 weeks ago - NKGen Appoints Dr. Anita Fletcher as National Principal Investigator for Phase 2a Troculeucel Trial Evaluating Moderate Alzheimer's Disease with AdventHealth Orlando as First East Coast Site - GlobeNewsWire
6 weeks ago - NKGen Biotech Announces Publication of Phase 1 Troculeucel Clinical Trial Results for the Treatment of Alzheimer's Disease - GlobeNewsWire
6 weeks ago - NKGen Biotech Receives U.S. FDA Fast Track Designation for Troculeucel for the Treatment of Moderate Alzheimer's Disease - GlobeNewsWire
4 months ago - NKGen Biotech Selected as Stalking Horse Bidder for NKMax - GlobeNewsWire